Drug Utilization Review Board
Minutes Draft

Name of Meeting:	Drug Utilization Review Board
Date of Meeting:	September 10, 2020
Length of Meeting:	2 hours and 47 minutes
Location of Meeting:	Electronic Meeting

Members Present:
Chethan Bachireddy, MD, Chief Medical Officer, Chair
Rachel Cain, PharmD
Denise Lowe, PharmD
Seth Brant, MD
Melissa Chouinard, MD
Michele Thomas, PharmD
Denese Gomes, NP
Kathryn Reid, PhD

Members Not Present:
Wendy Nash, PharmD
Randy Ferrance, MD

DMAS Attendees:
Donna Proffitt, RPh, Pharmacy Program Manager
Riva Kamat, MD, Pediatric Consultant
Andrew Ramsey, MD, MPH
Maryann McNeil, RPh, Pharmacist
Danielle Adeeb, CPhT, Pharmacy Contract Administrator
Nettie Emmelhainz, PharmD, Senior Pharmacy Policy and Data Analyst

Contractors:
Debbie Moody, RPh, Director, Clinical Account Services, Magellan Health Services
Nancy Eldin, PharmD, Pharmacist Account Executive, Magellan Health Services
Jeni Hodzic, CPhT, Lead Formulary Analyst, Magellan Health Services

Call to Order and Introductions

Dr. Rachel Cain took a roll call of the Committee members since this was an electronic meeting.

Dr. Kathryn Reid motioned to call the DUR meeting to order. Dr. Melissa Chouinard seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

Dr. Chethan Bachireddy called the meeting to order at 1:14 pm.

Minutes – June 11, 2020

Dr. Bachireddy motioned to approve the meeting minutes as submitted. Dr. Reid seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

DUR Board Updates

Dr. Bachireddy welcomed and thanked everyone for attending the electronic meeting.

RetroDUR Criteria Estimates

Dr. Nancy Eldin reviewed the Criteria Exception Estimates Reports with the DUR Board. The reports were broken down to the Top 40 Criteria Exception Estimates by Members and the Top 40 Criteria Exception Estimates by Total Payment Amount for Fee-For-Service (FFS) and each individual Managed Care Organization (MCO) plan.

The DUR Board members were interested conducting a re-review for the following three criteria that DMAS has lettered on in the past:

- Criteria number 7735 – Atypical antipsychotics without metabolic testing (lettered in July 2019)
- Criteria number 7910 – Diabetics ages 40 – 75 with no statins (lettered in December 2017)
- Criteria number 22451 – Diabetes and hypertension (by diagnosis) and no ACEI or ARB in history (lettered in September 2019)

The re-review information from these three criteria will be brought back for discussion at a future DUR meeting.

Members were interested in the following criteria for lettering:

- Criteria number 6814: SSRI non-compliance
- Criteria number 7032: Non-compliance with antihypertensive agents
- Criteria number 8026: Diabetes medication claims and no claims for blood glucose monitoring supplies

- Criteria number 8028: Insulin claims in the last 120 days without any claims for blood glucose monitoring supplies

Criteria number 7961(Update for Prescribers: ACC/AHA guidelines for blood pressure management) will be deactivated as this is an old criterion used back in 2018 to send educational letters about the updates to the guidelines to all physicians prescribing antihypertensive medications.

Dr. Eldin also reviewed the Criteria Exception Estimates Report for Lab Values with the DUR Board.

The DUR Board members requested to see if the Criteria Exception Estimates Reports can be grouped by disease states. Magellan will discuss with the Business Owner of FIQ (Annette Paul) to see if this can be done.

Dr. Eldin reviewed the Hemoglobin A1c Lab Value Over 9 and On Diabetic Meds for 6 Months Report. Dr. Cain mentioned that the MCOs are working on creating this same report for comparison.

Dr. Eldin reviewed the FFS members with a diagnosis of diabetes in the last 6 months report.

New Drugs

The DUR Board reviewed Koselugo™ (selumetinib), Oriahnn™ (elagolix, estradiol, and norethindrone acetate; elagolix), Pemazyre™ (pemigatinib), Qinlock™ (ripretinib), Retevmo™ (selpercatinib), Tabrecta™ (capmatinib), and Tukysa™ (tucatinib).

The DUR Board discussed the service authorization (SA) criteria and the Impact Reports for Koselugo™. The DUR Board members discussed removing question number 1 (Is the prescriber an oncologist?) from the SA criteria. Dr. Cain motioned to accept the service authorization criteria with the removal of question number 1 (Is the prescriber an oncologist?). Dr. Chouinard seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

The DUR Board discussed the SA criteria and the Impact Reports for Oriahnn™. Since Oriahnn™ is for premenopausal women, the DUR Board members discussed changing the wording to questions number 8 and 14 in reference to making sure the member does not have osteoporosis and has a Z score to “Is there a prescriber attestation that the member does not have osteoporosis?”. Dr. Denese Gomes motioned to accept the service authorization criteria and change the wording to questions 8 and 14 to “Is there a prescriber attestation that the member does not have osteoporosis?”. Dr. Michele Thomas seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

The DUR Board discussed the SA criteria and the Impact Reports for Pemazyre™. The DUR Board members discussed adding a specific note to questions number 8 and 14 in reference to the member having a comprehensive ophthalmological exam prior to initiation of therapy, every 2 months for the first 6 months of therapy, and every 3 months after. Dr. Gomes motioned to accept the SA criteria and add a note to questions number 8 and 14 in reference to the member having a comprehensive ophthalmological exam prior to initiation of therapy, every 2 months for the first 6 months of therapy, and every 3 months after. Dr. Thomas seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

The DUR Board discussed the SA criteria and the Impact Reports for Qinlock™. The DUR Board members discussed changing the wording to question number 4 from “≥ 3 prior therapies” to “≥ 3 kinase inhibitors” and also providing space under question number 4 to let the prescriber list the drugs the member has tried. Also, update the wording for question number 6 from “member will have a dermatologic evaluation” to “member has had a dermatologic evaluation”. Dr. Cain motioned to accept the SA criteria with the addition of changing the wording to question number 4 from “≥ 3 prior therapies” to “≥ 3 kinase inhibitors” and also providing space under question number 4 to let the prescriber list the drugs the member has tried and update the wording for question number 6 from “member will have a dermatologic evaluation” to “member has had a dermatologic evaluation. Dr. Reid seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

The DUR Board discussed the SA criteria and the Impact Reports for Retevmo®. Dr. Thomas motioned to accept the service authorization criteria for Retevmo®. Dr. Reid seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

The DUR Board discussed the SA criteria and the Impact Reports for Tabrecta™. Dr. Reid motioned to accept the service authorization criteria for Tabrecta™. Dr. Thomas seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

The DUR Board discussed the SA criteria and the Impact Reports for Tukysa™. The DUR Board members discussed changing the “OR” between the sub-questions for the different drug-drug interactions to “AND” for question number 4. Also, to update the wording for questions number 5 and 7 to mirror the wording in the package insert. Dr. Thomas made a motion to accept the service authorization criteria with the addition of changing the “OR” between the sub-questions for the different drug-drug interactions to “AND” for question number 4

and to update the wording for questions number 5 and 7 to mirror the wording in the package insert. Dr. Reid seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

New Drugs: DUR Drugs with New Generics; DUR Drugs with New Dosage Forms/Strengths; Biosimilars; New PDL-Eligible Drugs and New Physician Administered Drugs

The DUR Board reviewed the new drugs in this section and had no questions.

Specialty Drugs

MRx Pipeline - The DUR Board reviewed the July 2020 MRx Pipeline Report and the May 2020 MRx Pipeline + Bonus COVID-19 Report. Donna Proffitt gave a brief explanation on the coverage of drugs under the Pharmacy side versus the medical benefit at DMAS. Presently, the PBMS contract with Magellan does not include management of the drugs covered exclusively under the medical benefit. Dr. Thomas requested that Magellan separate the drugs under the pharmacy benefit versus the medical benefit under the MRx Pipeline for future meetings.

Topics for Discussion

Concurrent Use of Opioids and Benzodiazepines - The DUR Board reviewed Concurrent Use of Opioids and Benzodiazepines utilization reports for FFS and MCOs. The DUR Board decided to review this report twice a year.

Concurrent Use of Opioids and Antipsychotics - The DUR Board reviewed Concurrent Use of Opioids and Antipsychotics utilization reports for FFS and MCOs. The DUR Board decided to review this report twice a year.

Antipsychotic Medications in Children – The DUR Board reviewed the Antipsychotic Medications in Children reports for FFS and MCOs. The DUR Board decided to review this report twice a year.

DUR Quarterly Newsletters – The June 2020 newsletter was provided in the binder for review.

Surveillance

Opioid Use with Risk Factors and No Naloxone or Getting Naloxone - The DUR Board reviewed Opioid Use with Risk Factors and No Naloxone or Getting Naloxone reports for FFS and MCOs. The DUR Board requested a report looking at the number of hits for the new ProDUR edits (opioids with antipsychotics and opioid naïve with the messaging to offer naloxone).

Synagis® – The DUR Board reviewed the Synagis® Utilization Report for last season. The DUR Board discussed the Synagis® SA criteria and decided to remove question number 2 “Is the infant’s gestational age 29 weeks up to 31 weeks, 6 days and chronological age less than 6 months old?”, to be in accordance with the AAP guidelines. Dr. Thomas motioned to accept the service authorization criteria with the update to remove question number 2 “Is the infant’s gestational age 29 weeks up to 31 weeks, 6 days and chronological age less than 6 months old?”. Dr. Cain seconded the motion. (Reference Attachment 1 for the Committee Vote Tally)

Reports

ProDUR, RetroDUR and Utilization Analysis Reports – These reports were provided in the binder for review. These reports are requirements for the CMS Annual Report.

Next DUR Meeting

December 10, 2020

Dr. Chouinard motioned to adjourn the meeting. Dr. Cain seconded the motion. Dr. Cain adjourned the meeting at 4:01 pm. (Reference Attachment 1 for the Committee Vote Tally)

Attachment 1 – Committee Vote Tally

Committee Vote Taken:	Chethan Bachireddy, MD (Chair)	Rachel Cain, PharmD	Denise Lowe, PharmD	Seth Brant, MD	Melissa Chouinard, MD	Michele Thomas, PharmD	Denese Gomes, NP	Kathryn Reid, PhD
Called DUR Meeting to Order	A	A	A	A	S	A	A	M
DUR Committee Meeting Minutes from June 11, 2020	M	A	A	A	A	A	A	S
Koselugo™ Service Authorization (SA) Criteria with removal of question number 1 (Is the prescriber an oncologist?)	A	M	A	A	S	A	A	A
Oriahnn™ SA criteria and changing the wording to questions 8 and 14 to "Is there a prescriber attestation that the member does not have osteoporosis?"	A	A	A	A	A	S	M	A
Pemazyre™ SA Criteria and adding a note to questions 8 and 14 in reference to the member having a comprehensive ophthalmological exam prior to initiation of therapy, every 2 months for the first 6 months of therapy, and every 3 months after.	A	A	A	A	A	S	M	A
Qinlock® SA criteria with the addition of changing the wording to question number 4 from "≥ 3 prior therapies" to "≥ 3 kinase inhibitors" and also providing space under question number 4 to let the prescriber list the drugs the member has tried and update the wording for question number 6 from "member will have a dermatologic evaluation" to "member has had a dermatologic evaluation.	A	M	A	A	A	A	X	S
Retevmo® SA criteria	A	A	A	A	A	M	A	S
Tabrecta™ SA Criteria	A	A	A	A	A	S	A	M
Tukysa™ SA criteria with the addition of changing the "OR" between the sub-questions for the different drug-drug interactions to "AND" for question number 4 and to update the wording for questions number 5 and 7 to mirror the wording in the package insert.	A	A	A	A	A	M	A	S
Synagis® SA criteria and remove question number 2 "Is the infant's gestational age 29 weeks up to 31 weeks, 6 days and chronological age less than 6 months old?", to be in accordance with the AAP guidelines	A	S	A	A	A	M	A	A
Motion to Adjourn Meeting	A	S	A	A	M	A	A	A

KEY

M = member made motion

S = member seconded motion

A = member approved

D = member voted against

X = member did not vote